Mark Clark News
-
Bayer AG’s first-quarter profit fell short of analysts’ estimates as a crop of new medicines struggled to offset lagging older drugs and plunging earnings at the plastics unit.
-
Flu-stricken Americans and rising cancer drug sales helped Roche Holding AG boost revenue by 5.1 percent in a first quarter marked by approvals for two new breast-tumor drugs.
-
No gold miner in the world is offering acquirers faster growth at a cheaper price than Australia’s Regis Resources Ltd.
-
The Obama administration has committed to ending the presence of U.S. forces in Afghanistan in 2014. Basically, the White House is conceding that there will be no victory over the Taliban.
-
Shire Plc, a maker of drugs for rare genetic diseases, bought Sweden’s Premacure AB to gain an experimental treatment against a blindness-causing disorder in babies born prematurely.
-
The sea border that has become the main battleground between North and South Korea 57 years after it was imposed by a U.S. general has been called legally indefensible by American officials for more than three decades.
-
GlaxoSmithKline Plc, the U.K.’s largest drugmaker, said sales and profit will rise this year as the company awaits regulators’ approval of six drugs.
-
Amylin Pharmaceuticals Inc. has lured suitors such as Pfizer Inc., AstraZeneca Plc and Sanofi, which signed confidentiality agreements on the drugmaker’s sale process, said people familiar with the matter.
-
AstraZeneca Plc , the U.K.’s second- largest drugmaker, may double spending on share buybacks this year after a legal victory protecting the patent on the Crestor cholesterol pill freed up more cash, analysts said.
-
GlaxoSmithKline Plc , the U.K.’s largest drugmaker, expects to record a 1.57 billion-pound ($2.4 billion) charge in the second quarter to settle cases including claims that its Avandia diabetes treatment led to heart attacks.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page